Compare
Processa Pharmaceuticals, Inc. vs Dermata Therapeutics, Inc. vs Silo Pharma, Inc. vs Rocket One Inc.
| Latest fiscal year | Processa Pharmaceuticals, Inc. PCSA | Dermata Therapeutics, Inc. DRMA | Silo Pharma, Inc. SILO | Rocket One Inc. RKTO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $72.1K | n/a |
| Revenue growth (YoY) | n/a | n/a | 0.0% | n/a |
| Gross margin | n/a | n/a | 38.6% | n/a |
| Operating margin | n/a | n/a | n/m | n/a |
| Net margin | n/a | n/a | n/m | n/a |
| Net income | -$13.56M | -$7.56M | -$4.23M | -$12.47M |
| EPS (Diluted) | -$10.36 | -$8.16 | -$0.50 | -$0.90 |
| Operating cash flow | -$11.39M | -$7.76M | -$4.66M | -$9.80M |
| Free cash flow | n/a | n/a | n/a | n/a |
| Cash & equivalents | $5.54M | $7.52M | $4.75M | $6.25M |
| Total assets | $7.81M | $7.86M | $7.61M | $7.60M |
| Total liabilities | $2.24M | $1.64M | $1.30M | $1.45M |
| Shareholders' equity | $5.58M | $6.22M | $6.31M | $6.15M |
| Return on year-end equity | -243.2% | -121.5% | -67.0% | -202.7% |
| Shares outstanding | 2.57M | 2.66M | 13.32M | 15.51M |
Revenue, most recent five fiscal years
| Fiscal year | Processa Pharmaceuticals, Inc. | Dermata Therapeutics, Inc. | Silo Pharma, Inc. | Rocket One Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2022-12-31 | n/a | $72.1K Ended 2025-12-31 | n/a |
| 1 year earlier | $0 Ended 2021-12-31 | n/a | $72.1K Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | n/a | $72.1K Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | n/a | $72.1K Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | n/a | n/a | n/a |